Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference

Bright Minds Biosciences Inc. (DRUG) — NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that it will participate in the Foundation for Prader-Willi Research (FPWR) 2026 Research Symposium, October 7-8, and the P

Source: GlobeNewswire — read the full announcement there.

See our Bright Minds Biosciences company profile for background, links, and more Bright Minds Biosciences news.